Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report that membrane depolarization triggered IKC intracellular signals mediated by small GTPases of the Ras subfamily and protein kinase B (Akt) to advance the development of filopodia and lamellipodia in Chinese hamster ovary cells, stimulate their motility, and enhance neurite outgrowth in mouse neuroblastoma Neuro2a cells.
|
31682765 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we found NLGN3 promoted neuroblastoma cell proliferation and growth through activating PI3K/AKT pathway and providing a new target for neuroblastoma therapy.
|
31150649 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous report revealed that <i>Drynaria fortunei</i> (Polydiaceae) protected against 6-hydroxydopamine (6-OHDA)-induced oxidative damage via the PI3K/AKT pathway in B35 neuroblastoma cells.
|
30301204 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we measured the expression level of GIGYF1, Grb10, phosphorylated IGF1R/IGF1R, phosphorylated AKT serine/threonine protein kinase/protein kinase B (AKT)/AKT, and phosphorylated extracellular signal-regulated kinase (ERK)/ERK in human neuroblastoma SHSY-5Y cells.
|
30376373 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proximity ligation and two-way immunoprecipitation assays using monoclonal antibodies against gB and Akt-1 phosphorylated at S473 [Akt-1(S473)] confirmed that HSV-1(McKrae) gB interacted with Akt-1(S473) during virus entry into human neuroblastoma (SK-N-SH) cells and induced the release of intracellular calcium.
|
29321326 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study was aimed to explore the neuroprotective effect of AA against aluminium maltolate <b>(</b>Al(mal)<sub>3</sub>) induced neurotoxicity by assessing cell viability, mitochondrial membrane potential, levels of reactive oxygen species (ROS), DNA damage and apoptosis (Hoechst and dual staining, comet assay; expressions of pro-apoptotic, anti-apoptotic and signaling indices) via AKT/GSK-3β signaling pathway in SH-SY 5Y neuroblastoma cells.
|
28930619 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SD also inhibited AKT activation in neuroblastoma cells as shown by reduced phosphorylated AKT levels.
|
29335887 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The detected variants are located within the different domains of TIAM1 that signal to the upstream regulator RAS and downstream effector molecules MYC and RAC, which are all implicated in neuroblastoma etiology and progression.
|
28423360 |
2017 |
Central neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In contrast to RAS-MAPK pathway-mutated neuroblastoma cell lines, ALK-addicted neuroblastoma cells treated with trametinib showed increased activation (inferred by phosphorylation) of the kinases AKT and ERK5.
|
29184034 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We then demonstrate that the uptake of NB exosomes by MSCs was associated with a rapid increase in ERK1/2 and AKT activation, and that blocking ERK1/2 but not AKT activation inhibited the IL-6 and IL-8/CXCL8 production by MSCs without affecting exosome uptake.
|
28717423 |
2017 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Afatinib also induced apoptosis and blocked EGF-induced activation of PI3K/AKT/mTOR signaling in all neuroblastoma cell lines tested.
|
27902463 |
2017 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PAG1 knockdown in NB cells promotes proliferation and anchorage-independent colony formation with increased activation of AKT and ERK downstream of c-Src, while PAG1 overexpression significantly rescues these effects.
|
26993602 |
2016 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCH motif-containing molecule at the carboxyl terminal region 1 (BMCC1)/PRUNE2 is highly expressed in patients with favorable neuroblastoma (NB), encoding a multifunctional scaffold protein that modulates several signaling networks including RhoA and AKT pathways.
|
27453342 |
2016 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, whole-genome transcriptome analysis revealed that BRG1 controls the expression of key elements of oncogenic pathways such as PI3K/AKT and BCL2, which offers a promising new combination therapy for high-risk NB.
|
26996667 |
2016 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of the PI3K target AKT is frequent in neuroblastoma (NB) and correlates with poor prognosis.
|
25622909 |
2015 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This growth effect was accompanied by a marked decrease in the expression of MYC, MYCN, AKT and an increase in p53 expression in neuroblastoma cell lines without TP53 mutation.
|
24173829 |
2014 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
|
25228590 |
2014 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously demonstrated an increased expression of gastrin-releasing peptide (GRP) and its receptor, GRPR, in neuroblastoma and that GRP activates the PI3K-AKT pathway as a proangiogenic factor during tumor progression.
|
24108003 |
2013 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inactivation of FOXO3a by AKT was essential for neuroblastoma cell survival.
|
23378341 |
2013 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, activation of AKT (pAKT) positively correlated with neuroblastoma progression in an in vivo tumor-metastasis model.
|
24039782 |
2013 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, PI3K/AKT-dependent oncogenic transformations require N-myc, an extensively studied oncogene in neuroblastoma.
|
23468863 |
2013 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Reduction of Akt1 phosphorylation and apoptosis resistance were also evident when a neuroblastoma SH-SY5Y clone overexpressing WT LRRK2 was transfected with the I2020T LRRK2.
|
23220480 |
2013 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.
|
21993994 |
2012 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined epidermal growth factor receptor (EGFR), Kirsten rate sarcoma viral oncogene homolog (KRAS), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), PIK3CA, v-akt murine thymoma vial oncogene homolog 1 (AKT1), v-ras neuroblastoma viral oncogene homolog (NRAS), dual specificity mitogen-activated protein kinase kinase 1 (MEK1), and anaplastic lymphoma kinase (ALK) in patients with adenocarcinoma of the lung to identify driver mutations.
|
22135231 |
2012 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway.
|
22394107 |
2012 |